Larimar Therapeutics (STU:ZA71) ROCE % : -34.34% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Larimar Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -34.34%.

Larimar Therapeutics ROCE % Historical Data

The historical data trend for Larimar Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics ROCE % Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-90.18

-63.60

-40.33

-40.63

Larimar Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-41.30	-60.93	-41.64	-43.82	-34.34

Larimar Therapeutics ROCE % Calculation

Larimar Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-38.292	/	( ( (119.326 - 10.106)	+	(87.972 - 8.717) )	/ 2 )
	=	-38.292	/	( (109.22	+	79.255)	/ 2 )
	=	-38.292	/	94.2375
	=	-40.63 %

Larimar Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-65.824	/	( ( (220.323 - 19.653)	+	(197.338 - 14.673) )	/ 2 )
	=	-65.824	/	( ( 200.67	+	182.665 )	/ 2 )
	=	-65.824	/	191.6675
	=	-34.34 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Larimar Therapeutics (STU:ZA71) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Larimar Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines